Provided by Tiger Trade Technology Pte. Ltd.

Cullinan Therapeutics

15.53
+0.07000.45%
Post-market: 15.52-0.0100-0.06%19:30 EDT
Volume:567.53K
Turnover:8.84M
Market Cap:999.43M
PE:-4.48
High:15.95
Open:15.41
Low:15.24
Close:15.46
52wk High:23.19
52wk Low:6.73
Shares:64.35M
Float Shares:48.08M
Volume Ratio:0.46
T/O Rate:1.18%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4680
EPS(LYR):-3.7236
ROE:-50.30%
ROA:-31.36%
PB:3.11
PE(LYR):-4.17

Loading ...

Cullinan Therapeutics Price Target Maintained With a $37.00/Share by Wedbush

Dow Jones
·
Jun 11

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Jun 11

U.S. RESEARCH ROUNDUP-Arthur J. Gallagher & Co, Datadog, Oracle

Reuters
·
Jun 11

Cullinan Therapeutics price target raised to $46 from $33 at Clear Street

TIPRANKS
·
Jun 11

BUZZ-U.S. STOCKS ON THE MOVE-Illumina, Cullinan, BorgWarner

Reuters
·
Jun 11

Analysts’ Top Healthcare Picks: Dianthus Therapeutics (DNTH), Cullinan Management (CGEM)

TIPRANKS
·
Jun 11

BUZZ-Cullinan rises as early-stage data show remission in autoimmune disease drugs

Reuters
·
Jun 10

Cullinan Therapeutics releases Immunology Day presentation

Reuters
·
Jun 10

Cullinan Therapeutics Reports Early Positive Autoimmune Drug Data, Plans Next Trial Steps

MT Newswires Live
·
Jun 10

Cullinan Therapeutics Highlights Positive Early Autoimmune Trial Data

TIPRANKS
·
Jun 10

Cullinan Therapeutics reports CLN-978, velinotamig data

TIPRANKS
·
Jun 10

Cullinan shares Phase 1 data showing CLN-978 induces remission in difficult-to-treat rheumatoid arthritis patients

Reuters
·
Jun 10

Cullinan: Sees Additional Multi-Dose Data for Cln-978 in Ra Next Quarter and in Sle in Q4, Additional Data for Velinotamig Before End of Year

THOMSON REUTERS
·
Jun 10

Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting Cd19 and Bcma in Autoimmune Diseases

THOMSON REUTERS
·
Jun 10

Cullinan Therapeutics Inc: Cln-978 (Cd19 Tce) Eular Data Demonstrated Potential for Immune Reset, Including Remissions, in Both Sle and Ra

THOMSON REUTERS
·
Jun 10

Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseases

GlobeNewswire
·
Jun 10

Cullinan Showcases Promising CLN-978 Phase 1 Autoimmune Data

TIPRANKS
·
Jun 08

Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX), Amylyx Pharmaceuticals Inc (AMLX) and Cullinan Management (CGEM)

TIPRANKS
·
Jun 08

Cullinan Therapeutics Shares Rise on Positive Early Trial Data for Autoimmune Drug

Dow Jones
·
Jun 08

Cullinan Therapeutics Price Target Maintained With a $30.00/Share by HC Wainwright & Co.

Dow Jones
·
Jun 08